BML Capital Management’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

BML Capital Management’s Portfolio KNTE Stock Details KNTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-498,851	Closed	-$1.33M	–	34
2024 Q1	$1.33M	Buy	498,851 +30,641	+7%	+$75.9K	0.88%	19
2023 Q4	$1.11M	Buy	+468,210	New	+$829K	0.84%	23

BML Capital Management's KNTE Position: Q2 2024 in Review

BML Capital Management sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 498,851 shares — an estimated $1.33M sold.

BML Capital Management first reported a position in KNTE in Q4 2023 and held it in 2 quarters. The position peaked at $1.33M in Q1 2024. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.

BML Capital Management reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
BML Capital Management sold 498,851 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $1.33M.
BML Capital Management first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2023 and held it in 2 quarters.
BML Capital Management's Kinnate Biopharma Inc. Common Stock position peaked at $1.33M in Q1 2024.
0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.

Based on BML Capital Management's 13F filing for Q2 2024, filed 7 Aug 2024.